通过天眼查大数据分析，北京东方通科技股份有限公司共对外投资了12家企业，参与招投标项目461 次，知识产权方面有商标信息81条，专利信息169条，此外企业还拥有行政许可12个。 金融界消息 截至2025年6月5日收盘，*ST东通（300379）报收于5.44元，下跌2.68%，换手率6.5%，成 交量34.24万手，成交金额1.87亿元。 *ST东通最新一期业绩显示，截至2025一季报，公司营业总收入1.34亿元、同比增长77.41%，归属净利 润3054.31万元，同比增长58.12%，扣非净利润4235.77万元，同比增长45.14%，流动比率7.857、速动比 率7.294、资产负债率11.50%。 天眼查商业履历信息显示，北京东方通科技股份有限公司，成立于1997年，位于北京市，是一家以从事 科技推广和应用服务业为主的企业。企业注册资本55792.2828万人民币，实缴资本10683.1544万人民 币。公司法定代表人为黄永军。 资金流向方面，今日主力资金净流出2120.44万元，占比成交额11.35%。其中，超大单净流出294.47万 元、占成交额1.58%，大单净流出1825.97万元、占成交额9 ...

Financial Performance - The Group's revenue from continuing operations increased by 91.6% to HK$101.0 million in 2024, compared to HK$52.7 million in 2023[11]. - The Group's gross profit from continuing operations rose by 20.0% to HK$21.3 million in 2024, up from HK$17.8 million in 2023[11]. - The net loss from continuing operations increased by 100.0% to HK$80.8 million in 2024, compared to HK$40.4 million in 2023[11]. - The Group recorded a net loss from continuing operations attributable to the owners of the Company of HK$80.8 million in 2024, an increase of 100.0% from HK$40.4 million in 2023[30]. - Other income from continuing operations decreased to HK$166,000 in 2024 from HK$1.8 million in 2023, mainly from interest income[36]. - The Group reported a net loss of HK$25.6 million from other gains and losses in 2024, compared to a loss of HK$12.9 million in 2023[41]. Segment Performance - The distribution segment recorded a net loss of HK$19.3 million in 2024, worsening from a loss of HK$5.0 million in 2023[13]. - The manufacturing segment reported a net loss of HK$4.7 million in 2024, slightly increasing from a loss of HK$4.6 million in 2023[13]. - The investment segment experienced a net loss of HK$20.5 million in 2024, compared to a loss of HK$8.5 million in 2023[13]. - The financial leasing segment recorded a net loss of HK$14.3 million in 2024, a significant decline from a profit of HK$2.4 million in 2023[13]. - Revenue from the Distribution Segment rose by 105.7% to HK$88.4 million in 2024, driven by increased sales of health and wellness products and stabilized supply of traditional Chinese medical products[23]. - The Manufacturing Segment recorded revenue of HK$6.4 million in 2024, up 119.8% from HK$2.9 million in 2023, attributed to broader product diversity and customer base[24]. - The Investment Segment's revenue decreased by 9.7% to HK$6.2 million in 2024, with a net loss of HK$20.5 million, primarily due to a fair value loss on investment properties[28]. - The Financial Leasing Segment reported a net loss of HK$14.3 million in 2024, compared to a profit of HK$2.4 million in 2023, mainly due to interest costs and fair value losses[29]. Assets and Liabilities - The total assets of the Group as of December 31, 2024, were HK$392.5 million, a decrease of 22.0% from HK$502.8 million as of December 31, 2023[47]. - Total liabilities increased by 3.4% to HK$51.6 million as of December 31, 2024, from HK$49.9 million as of December 31, 2023[47]. - The gearing ratio increased from 9.9% as of December 31, 2023, to 13.1% as of December 31, 2024[48]. - Cash and cash equivalents and deposits with non-bank financial institutions totaled approximately HK$13.2 million as of December 31, 2024, down from HK$28.4 million in 2023[53]. Corporate Governance - Mr. Wong Lik Ping has been serving as both Chairman and CEO since the resignation of former CEO Mr. Lai Ka Fai on July 31, 2023, while the company is in the process of nominating a suitable candidate for the CEO position[136]. - The Board currently has three Independent Non-Executive Directors (INEDs), with one holding appropriate professional qualifications or expertise in accounting or related financial management[140]. - All INEDs have confirmed their independence annually, and the company considers that they meet the independence guidelines set out in Rule 3.13 of the Listing Rules[141]. - The company has established procedures for Directors to obtain independent professional advice at the company's expense to assist in discharging their duties[132]. - The Board held meetings as necessary, providing at least 14 days' notice for regular meetings, allowing Directors to include matters for discussion in the agenda[134]. - The Audit Committee consists of three independent non-executive directors, ensuring oversight of financial reporting and compliance[168]. - The Company has adopted a Board Diversity Policy to enhance the skills and perspectives of board members[153]. - The Director Nomination Policy ensures a balanced and diverse Board, with regular reviews to meet business needs[158]. - The Remuneration Committee, comprising the Chairman and two independent non-executive directors, reviewed director remuneration packages during the year[165]. Risk Management - The Group's risk management framework includes the Board, the Audit Committee, and Senior Management, ensuring comprehensive oversight[183]. - The internal control consultant identified deficiencies and proposed improvements, with management taking remedial actions accordingly[186]. - The Board concluded that there are no material irregularities affecting the Group's state of affairs, and the risk management systems are effective and adequate[186]. - The Company regularly reminds directors and relevant staff about compliance with insider information regulations[186]. - The Audit Committee reviewed risk management and internal control matters, ensuring alignment with corporate governance standards[174]. Future Outlook and Strategy - The Group plans to steadily expand its existing business, particularly in the distribution and manufacturing segments[16]. - The Group aims to diversify income sources and pursue long-term growth through cautious exploration of new growth opportunities[16]. - The Group plans to offload certain real estate properties in the PRC to replenish liquidity and mitigate increasing market risks[100]. - The Group aims to optimize business segments to enhance volume and profitability while considering withdrawal from loss-making projects[102]. - The economic outlook for Hong Kong in 2025 indicates challenges such as weak domestic consumption and a sluggish property market, despite a stable unemployment rate around 3%[90]. - The PRC's economy faces risks from geopolitical tensions and global protectionism, but government measures aim to stimulate domestic demand and support the high-end technology sector[91].

Financial Performance - Total revenue for the year ended December 31, 2024, was HKD 100,977,000, representing an increase of 91.5% compared to HKD 52,702,000 in 2023[3] - Gross profit for the year was HKD 21,319,000, up 20.8% from HKD 17,769,000 in the previous year[3] - The company reported a loss from continuing operations before tax of HKD 80,794,000, which is a 97.7% increase compared to a loss of HKD 40,887,000 in 2023[3] - The net loss for the year was HKD 80,813,000, compared to a net loss of HKD 37,296,000 in 2023, indicating a 116.5% increase in losses[4] - Basic and diluted loss per share from continuing and discontinued operations was HKD 4.79, compared to HKD 2.29 in the previous year[4] Asset and Liability Changes - Non-current assets decreased to HKD 324,253,000 from HKD 404,124,000, reflecting a decline of 19.7%[6] - Current assets decreased to HKD 68,203,000 from HKD 98,707,000, a reduction of 30.9%[6] - Total liabilities decreased to HKD 48,156,000 from HKD 49,888,000, a slight decline of 3.5%[7] - The company's total equity decreased to HKD 340,881,000 from HKD 452,943,000, representing a decrease of 24.7%[7] - Total assets decreased from HKD 502,831 thousand in 2023 to HKD 392,456 thousand in 2024, representing a decline of approximately 22%[25] - Total liabilities increased slightly from HKD 49,888 thousand in 2023 to HKD 51,575 thousand in 2024, an increase of about 3.4%[25] Revenue Sources - Revenue from the sale of daily necessities, healthcare, and hygiene products amounted to HKD 88,360,000, up from HKD 42,948,000, representing a growth of 105.4%[15] - Revenue from food products and nutritional supplements increased to HKD 6,397,000 from HKD 2,910,000, marking a rise of 119.5%[15] - The revenue from customer contracts recognized at a point in time was HKD 94,757,000, compared to HKD 45,858,000 in the previous year, reflecting a growth of 106.5%[16] - The distribution segment generated revenue of HKD 88,400,000 in 2024, a 105.7% increase from HKD 42,900,000 in 2023[50] - The production segment reported revenue of HKD 6,400,000 in 2024, a 119.8% increase from HKD 2,900,000 in 2023[51][57] Operational Challenges - The company reported a significant increase in depreciation expenses, rising from HKD 5,103 thousand in 2023 to HKD 4,282 thousand in 2024, a decrease of approximately 16%[26] - Interest income from banks and non-bank financial institutions dropped sharply from HKD 1,656 thousand in 2023 to HKD 116 thousand in 2024, a decline of about 93%[27] - The company incurred a loss of HKD 15,013 thousand due to goodwill impairment in 2024, compared to no such loss in 2023[26] - The company recognized a loss of HKD 3,375 thousand from the disposal of an associate in 2024, compared to a loss of HKD 691 thousand in 2023[27] - The company’s total other income decreased from HKD 3,703 thousand in 2023 to HKD 166 thousand in 2024, a decline of approximately 95%[27] Tax and Dividends - The effective tax expense for the year was HKD 19 thousand in 2024, compared to a tax credit of HKD 480 thousand in 2023[29] - The company reported a loss attributable to shareholders of HKD 80,813,000 for the year 2024, compared to a loss of HKD 38,601,000 in 2023, representing an increase in loss of 109%[32] - The company did not declare or propose any dividends for the year ending December 31, 2024, consistent with 2023[33] Employee and Operational Efficiency - Total employee costs decreased from HKD 24,509 thousand in 2023 to HKD 22,030 thousand in 2024, a reduction of approximately 10%[31] - The company's administrative and other operating expenses from continuing operations were HKD 44,700,000 in 2024, a decrease of 7.3% from HKD 48,200,000 in 2023[60] - The group employed approximately 59 employees as of December 31, 2024, a decrease from 62 employees in 2023[86] Future Outlook and Strategic Initiatives - The company is optimistic about the local economic outlook despite challenges, with government support measures in place to stimulate demand[77] - The group is considering selling several properties in China to supplement liquidity and mitigate increasing market risks in the real estate sector[79] - The group aims to optimize its business segments to enhance sales and profitability while seeking to reduce costs further[79] - The group is committed to diversifying revenue sources and creating profits for long-term sustainable growth and enhancing overall shareholder value[79] Compliance and Governance - The audit committee has reviewed and approved the consolidated financial statements for the year ending December 31, 2024[94] - The financial figures in the announcement have been agreed upon by the company's auditor, Zhonghui Anda CPA Limited[95] - The annual report containing all information required by the Stock Exchange Listing Rules will be sent to shareholders in due course[96] - The board of directors includes four executive directors and three independent non-executive directors as of March 26, 2025[98]

EGIC 中國恒嘉融資租賃集團有限公司 CHINA EVER GRAND FINANCIAL LEASING GROUP CO., LTD. (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) (Stock Code 股份代號：379) INTERIM REPORT 2024中期報告 CONTENTS 目錄 CONTENTS 目錄 | --- | --- | |----------------------------------------------------------|------------------------------| | | | | Corporate Information | 公司資料 | | Condensed Consolidated Statement of Profit or Loss | 簡明綜合損益表 | | Condensed Consolidated Statement of Profit or Loss | 簡明綜合損益及其他全面收益表 | | and Other ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：379） 截至二零二四年六月三十日止六個月之 中期業績公告 中國恒嘉融資租賃集團有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此提呈本公司 及其附屬公司（「本集團」）截至二零二四年六月三十日止六個月（「當前期間」）之未經審核 中期簡明綜合業績，連同二零二三年同期（「相應期間」）之比較數字如下： 簡明綜合損益表 截至二零二四年六月三十日止六個月 截至六月三十日止六個月 | --- | --- | --- | --- | |--------------|-------|--------------|--------------| | | | | | | | | | | | | | 二零二四年 | 二零二三年 | | | | （未經審核） | （未經審核） | | | 附註 | 千港元 | 千港元 | | | | | （經重列） | | 持續經營業務 | ...

Financial Performance - The financial leasing segment recorded a shared profit of HK$2.4 million, driven by interest income and fair value gains[19]. - The investment segment reported a net loss of HK$8.5 million in 2023, compared to a profit of HK$12.0 million in 2022[19]. - The distribution segment incurred a net loss of HK$5.0 million, an improvement from a loss of HK$7.1 million in 2022[19]. - The manufacturing segment recorded a net loss of HK$4.6 million, down from a loss of HK$7.6 million in 2022[19]. - The Group's total net loss from continuing operations was HK$40.4 million, compared to a loss of HK$31.6 million in 2022[19]. - The Group's revenue from continuing operations decreased by 26.5% to HK$52.7 million in 2023 compared to HK$71.7 million in 2022[26]. - The Group's gross profit from continuing operations decreased by 26.8% to HK$17.8 million in 2023 from HK$24.3 million in 2022[26]. - The net loss from continuing operations increased by 27.7% to HK$40.4 million in 2023 compared to HK$31.6 million in 2022[26]. - The Investment Segment's revenue decreased by 25.1% to HK$6.8 million in 2023, with a net loss of HK$8.5 million compared to a profit of HK$12.0 million in 2022[28]. - The Distribution Segment's revenue decreased by 29.0% to HK$42.9 million in 2023, with a net loss of HK$5.0 million, a decrease of 30.6% from HK$7.1 million in 2022[34]. - The Manufacturing Segment recorded revenue of HK$2.9 million in 2023, with a net loss of HK$4.6 million, an improvement from a loss of HK$7.6 million in 2022[35]. Corporate Strategy - The Group plans to focus on developing its own brand healthcare products and healthy instant noodles in the upcoming year[20]. - The Group aims to diversify income sources and pursue long-term growth through new potential opportunities and undervalued assets[20]. - The Group is actively seeking new growth opportunities and business expansion to diversify revenue sources and achieve long-term growth[23]. - The Group aims to enhance profitability by securing exclusive distributorships of proprietary Chinese medicines (PCMs) and expanding its distribution network in Hong Kong[149]. - The Group is investing in a production line for healthy instant noodles, expected to launch in Q2 2024, targeting health-conscious consumers[148]. - The Group plans to introduce more health and wellness products under its own brand, including gastrointestinal medical products and probiotics[149]. - A strategic partnership with Dan Dan Group has been established to enhance market presence and brand recognition through both physical and online retail channels[150]. Financial Position and Assets - The total assets of the Group decreased by HK$298.5 million to HK$502.8 million as of December 31, 2023, primarily due to the deconsolidation of BJEG Group[56]. - The gearing ratio improved significantly from 33.0% in 2022 to 9.9% in 2023, reflecting a deleverage effect from the deconsolidation[57]. - Total liabilities decreased to HK$49.9 million from HK$264.7 million, a reduction of HK$214.8 million, primarily due to the deconsolidation of BJEG Group[61]. - The capital-to-asset ratio improved significantly from 33.0% as of December 31, 2022, to 9.9% as of December 31, 2023[61]. - The current ratio increased from 1.3 to 2.0 during the same period, indicating improved liquidity[61]. - Cash and cash equivalents, along with other financial resources, decreased to approximately HK$28.4 million from HK$88.3 million year-over-year[62]. - The Group had no borrowings as of December 31, 2023, compared to HK$152.6 million in borrowings due within one year at a 9.0% interest rate in 2022[62]. - The Group's exposure to credit risk has been significantly reduced due to the deconsolidation of BJEG Group, which was previously classified as a non-wholly owned subsidiary[66]. Credit Risk Management - The expected credit loss (ECL) assessment is based on a probability-weighted expected credit losses model, which includes five key parameters[125]. - The company has a provision for impairment losses under ECL of HK$162,029,000 as of December 31, 2022, which is 100% of the total provision[123]. - The company is focused on managing its credit risk through individual assessments of receivables based on the ECL model[125]. - The finance department monitors loan repayments and conducts annual collateral valuations to ensure a loan-to-value ratio of at least 100%[109]. - The company conducts thorough credit risk assessments, including background checks and collateral evaluations, before approving loans[101]. Corporate Governance - The company complied with all code provisions of the Corporate Governance Code throughout the year, except for the separation of the roles of Chairman and CEO[189]. - The Board emphasized the importance of effective use of idle funds to enhance overall capital gain, ensuring sufficient working capital remains for business needs[171]. - The Board of Directors consists of five executive Directors, one non-executive Director, and four independent non-executive Directors[195]. - The company actively observes corporate governance developments in Hong Kong and overseas to maintain high standards[188]. - The Board is regularly updated on governance and regulatory matters[199].

Financial Performance - Total revenue for the year ended December 31, 2023, was HKD 52,702,000, a decrease of 26.5% from HKD 71,738,000 in 2022[3] - Gross profit for the same period was HKD 17,769,000, down 26.7% from HKD 24,262,000 in the previous year[3] - The loss from continuing operations for the year was HKD 40,408,000, compared to a loss of HKD 31,649,000 in 2022[4] - The company reported a total comprehensive loss of HKD 50,691,000 for the year, contrasting with a comprehensive income of HKD 20,913,000 in 2022[5] - The basic loss per share from continuing and discontinued operations was HKD (2.29), compared to earnings of HKD 0.42 in the previous year[4] - The company’s total equity decreased to HKD 452,943,000 from HKD 536,659,000, a decline of 15.6%[8] - The company recorded a pre-tax loss of 40,887 thousand HKD in 2023, compared to a loss of 31,032 thousand HKD in 2022, indicating a worsening financial performance[21] - The net loss for continuing operations in 2023 was HKD 40,400,000, an increase of 27.7% from HKD 31,600,000 in 2022, primarily due to adverse fair value changes in investment properties amounting to approximately HKD 25,000,000[72] - The loss attributable to the owners of the company for 2023 was HKD 38.6 million, compared to a profit of HKD 7.0 million in 2022[37] Revenue Breakdown - Total revenue for the year was HKD 57,239,000, a decrease of 26.5% from HKD 77,786,000 in the previous year[15] - Revenue from asset management consulting services increased significantly to HKD 1,942,000 from HKD 28,000[15] - Sales of food additives and nutritional enhancers rose to HKD 2,910,000 from HKD 2,130,000[15] - Revenue from daily necessities, healthcare, and hygiene products decreased to HKD 42,948,000 from HKD 60,474,000[15] - Interest income from financing lease receivables dropped to HKD 2,595,000 from HKD 6,020,000[15] - Rental income increased to HKD 5,825,000 from HKD 4,699,000[15] - Revenue from customer contracts in China was HKD 4,852,000, up from HKD 2,158,000[17] - Revenue from customer contracts in Hong Kong decreased to HKD 42,948,000 from HKD 60,474,000[17] Assets and Liabilities - Non-current assets decreased to HKD 404,124,000 from HKD 483,276,000 in the previous year, reflecting a decline of 16.4%[7] - Current liabilities were reduced to HKD 49,888,000 from HKD 249,369,000, indicating a significant decrease of 80%[8] - The company’s cash and cash equivalents stood at HKD 28,413,000, down from HKD 38,143,000 in 2022[7] - The total liabilities for the company in 2023 were 49,888 thousand HKD, a decrease from 264,676 thousand HKD in 2022, reflecting a reduction in financial obligations[24] - The investment segment's liabilities decreased to 10,463 thousand HKD in 2023 from 15,132 thousand HKD in 2022, showing a reduction in financial risk[24] - The total assets as of December 31, 2023, were HKD 502,800,000, a decrease of HKD 298,500,000 from HKD 801,300,000 in 2022[82] - Total liabilities decreased to HKD 49,900,000 in 2023 from HKD 264,700,000 in 2022, primarily due to the deconsolidation of Beijing Hengjia Group[82] Operational Focus and Strategy - The company plans to continue focusing on financing leasing and related consulting services in China, as well as expanding its investment activities[9] - The company plans to focus on resource allocation and performance monitoring across its segments to enhance operational efficiency[22] - The company is focusing on operations in China and Hong Kong, with a stable recovery in Hong Kong's economy since early 2023, particularly in retail and local tourism[99] - The company is investing in a new health instant noodle production line, expected to launch in Q2 2024, targeting health-conscious consumers[102] - The group aims to enhance sales through product diversification, diversified distribution channels, and expanding its customer base across different regions[103] - The group plans to launch more proprietary health and wellness products, including gastrointestinal medical products, probiotics, and NMN products[103] Governance and Compliance - The company has adhered to the Corporate Governance Code and all its provisions, with the exception of the separation of roles between the Chairman and the CEO, which is currently held by Mr. Wang Liping[116] - The Audit Committee, composed of three independent non-executive directors, has reviewed and approved the consolidated financial statements for the year ended December 31, 2023[121] - The company did not purchase, sell, or redeem any of its listed securities during the year ended December 31, 2023[120] - The remuneration committee does not review or provide recommendations on the remuneration of senior management, as the board believes that executive directors are more suitable for this task[117] - The company is in the process of nominating a suitable candidate for the CEO position following the resignation of the previous CEO on July 31, 2023[116] Employee and Training - The group employs approximately 62 staff members in Hong Kong and China, providing regular training to enhance their skills and knowledge[111] Market Conditions - The economic environment in China remains challenging, with issues such as a sluggish real estate market and geopolitical tensions affecting consumer confidence[99]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 379 （股份代號： ） 有關二零二三年中期業績公告及二零二三年中期報告 及業務更新之補充公告 茲提述本公司截至二零二三年六月三十日止六個月日期為二零二三年八月三十日之中期 業績公告（「二零二三年中期業績公告」）及截至二零二三年六月三十日止六個月之中期報 告（「二零二三年中期報告」）。除文義另有所指外，本公告所採用之詞彙與二零二三年中期 業績公告及二零二三年中期報告所界定者具有相同涵義。 本公告旨在提供二零二三年中期業績公告及二零二三年中期報告有關貿易分部之業務回 顧之補充資料。 貿易分部之業務回顧 截至二零二三年六月三十日止六個月之收入及分部虧損較截至二零二二年六月三十日止 (i) COVID-19 六個月有所減少，主要歸因於 疫情逐漸衰退，導致強制佩戴口罩政策放寬及 ...

CONTENTS 目錄 | Corporate Information | 公司資料 | 2 | | --- | --- | --- | | Condensed Consolidated Statement of Profit or Loss | 簡明綜合損益表 | 4 | | Condensed Consolidated Statement of Profit or Loss | 簡明綜合損益及其他全面收益表 | 5 | | and Other Comprehensive Income | | | | Condensed Consolidated Statement of Financial Position | 簡明綜合財務狀況表 | 6 | | Condensed Consolidated Statement of Changes in Equity | 簡明綜合權益變動表 | 8 | | Condensed Consolidated Statement of Cash Flows | 簡明綜合現金流量表 | 9 | | Notes to the Condensed Consolidated Finan ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 379 （股份代號： ） 截至二零二三年六月三十日止六個月之 中期業績公告 中國恒嘉融資租賃集團有限公司（「本公司」）董事會（「董事會」或「董事」）謹此公佈本公司 及其附屬公司（「本集團」）截至二零二三年六月三十日止六個月之未經審核簡明綜合業績 連同二零二二年同期之比較數字如下： 簡明綜合損益表 截至二零二三年六月三十日止六個月 截至六月三十日止六個月 二零二三年 二零二二年 （未經審核） （未經審核） 附註 千港元 千港元 4 25,046 50,343 收入 (19,526) (44,999) 收入成本 5,520 5,344 毛利 ...